From Yahoo Finance: 2025-06-07 04:15:00

Hims & Hers is a major player in the telehealth industry, experiencing significant growth and aiming to disrupt healthcare. Acquiring a company to expand into Europe, the stock, though expensive, shows potential for long-term investment. The company’s innovative approach offers direct-to-consumer prescription services and has seen substantial revenue growth.

With a focus on disrupting traditional healthcare models, Hims & Hers has gained traction in the telehealth market. Expanding offerings to include weight loss and other prescriptions, the company has a vast customer base and plans for international growth through a proposed buyout in Europe.

Boasting 2.4 million active customers, Hims & Hers is poised for significant growth, with a goal of reaching $6.5 billion in revenue by 2030. With expanding product lines and international partnerships, the company shows promise in revolutionizing healthcare delivery models, making it an exciting stock to watch.

Hims & Hers’ direct-to-consumer model and expansion plans through acquiring Zava in Europe signal the company’s ambitions to disrupt healthcare on a global scale. With impressive revenue growth and high expectations, the stock’s potential for long-term growth is evident, but careful consideration is advised before investing.

The Motley Fool Stock Advisor team has identified the top 10 stocks for investors to buy now, with high potential for returns. Noting the historical success of recommended stocks like Netflix and Nvidia, the team provides insights into potential market-crushing investments. Join Stock Advisor for access to the latest top 10 list and maximize your investment opportunities.

Read more: This Monster Growth Stock Is Up 167% in the Past Year and Disrupting the Healthcare Space